id	sid	eid	entity	type
dpc-1881	1	1	today	DATE
dpc-1881	1	2	claudio conforti	PERSON
dpc-1881	1	3	harald kittler melanoma:	ORG
dpc-1881	1	4	chryssoula papageorgiou	PERSON
dpc-1881	1	5	zoe apalla	PERSON
dpc-1881	1	6	sofia-magdalini manoli	PERSON
dpc-1881	1	7	vincenzo de falco	PERSON
dpc-1881	1	8	stefania napolitano	PERSON
dpc-1881	1	9	luigi pio guerrera	PERSON
dpc-1881	1	10	troiani	NORP
dpc-1881	1	11	pietro quaglino	PERSON
dpc-1881	1	12	paolo	PERSON
dpc-1881	1	13	luca tonella	PERSON
dpc-1881	1	14	marco rubatto	PERSON
dpc-1881	1	15	simone ribero	PERSON
dpc-1881	1	16	maria teresa	PERSON
dpc-1881	1	17	1885	DATE
dpc-1881	2	1	giuseppe argenziano	PERSON
dpc-1881	2	2	md dermatology unit	ORG
dpc-1881	2	3	university of campania luigi vanvitelli	ORG
dpc-1881	2	4	naples	GPE
dpc-1881	3	1	h. peter soyer	PERSON
dpc-1881	3	2	md	GPE
dpc-1881	4	1	the university of queensland diamantina institute	ORG
dpc-1881	4	2	alexandra hospital prof	PERSON
dpc-1881	5	1	paola queirolo	PERSON
dpc-1881	5	2	md	GPE
dpc-1881	5	3	the “divisione di oncologia medica del melanoma	ORG
dpc-1881	5	4	istituto europeo di oncologia	PERSON
dpc-1881	5	5	al contributo di melanoma	PERSON
dpc-1881	5	6	today	DATE
dpc-1881	5	7	claudio conforti	PERSON
dpc-1881	5	8	harald kittler melanoma:	ORG
dpc-1881	5	9	chryssoula papageorgiou	PERSON
dpc-1881	5	10	zoe apalla	PERSON
dpc-1881	5	11	sofia-magdalini manoli	PERSON
dpc-1881	5	12	vincenzo de falco	PERSON
dpc-1881	5	13	stefania napolitano	PERSON
dpc-1881	5	14	luigi pio guerrera	PERSON
dpc-1881	5	15	troiani	NORP
dpc-1881	5	16	pietro quaglino	PERSON
dpc-1881	5	17	paolo	PERSON
dpc-1881	5	18	luca tonella	PERSON
dpc-1881	5	19	marco rubatto	PERSON
dpc-1881	5	20	simone ribero	PERSON
dpc-1881	5	21	maria teresa	PERSON
dpc-1881	5	22	1885	DATE
dpc-1881	6	1	giuseppe argenziano	PERSON
dpc-1881	6	2	md dermatology unit	ORG
dpc-1881	6	3	university of campania luigi vanvitelli	ORG
dpc-1881	6	4	naples	GPE
dpc-1881	7	1	h. peter soyer	PERSON
dpc-1881	7	2	md	GPE
dpc-1881	8	1	the university of queensland diamantina institute	ORG
dpc-1881	8	2	alexandra hospital prof	PERSON
dpc-1881	9	1	paola queirolo	PERSON
dpc-1881	9	2	md	GPE
dpc-1881	9	3	the “divisione di oncologia medica del melanoma	ORG
dpc-1881	9	4	istituto europeo di oncologia	PERSON
dpc-1881	9	5	al contributo di melanoma	PERSON
dpc-1881	9	6	today	DATE
dpc-1881	9	7	claudio conforti	PERSON
dpc-1881	9	8	harald kittler melanoma:	ORG
dpc-1881	9	9	chryssoula papageorgiou	PERSON
dpc-1881	9	10	zoe apalla	PERSON
dpc-1881	9	11	sofia-magdalini manoli	PERSON
dpc-1881	9	12	vincenzo de falco	PERSON
dpc-1881	9	13	stefania napolitano	PERSON
dpc-1881	9	14	luigi pio guerrera	PERSON
dpc-1881	9	15	troiani	NORP
dpc-1881	9	16	pietro quaglino	PERSON
dpc-1881	9	17	paolo	PERSON
dpc-1881	9	18	luca tonella	PERSON
dpc-1881	9	19	marco rubatto	PERSON
dpc-1881	9	20	simone ribero	PERSON
dpc-1881	9	21	maria teresa	PERSON
dpc-1881	10	1	h. peter soyer	PERSON
dpc-1881	10	2	md	GPE
dpc-1881	11	1	the university of queensland diamantina institute	ORG
dpc-1881	11	2	alexandra hospital prof	PERSON
dpc-1881	12	1	paola queirolo	PERSON
dpc-1881	12	2	md	GPE
dpc-1881	12	3	the “divisione di oncologia medica del melanoma	ORG
dpc-1881	12	4	istituto europeo di oncologia	PERSON
dpc-1881	14	1	e2021164s 1	DATE
dpc-1881	14	2	pietro quaglino	PERSON
dpc-1881	14	3	paolo	PERSON
dpc-1881	14	4	luca tonella	PERSON
dpc-1881	14	5	marco rubatto	PERSON
dpc-1881	14	6	simone ribero	PERSON
dpc-1881	14	7	maria teresa	PERSON
dpc-1881	14	8	dermatologic clinic	ORG
dpc-1881	14	9	university of turin medical school	ORG
dpc-1881	14	10	turin	GPE
dpc-1881	14	11	italy	GPE
dpc-1881	14	12	quaglino	PERSON
dpc-1881	14	13	tonella l	DATE
dpc-1881	15	1	fierro mt	GPE
dpc-1881	17	1	july 10, 2021	DATE
dpc-1881	18	1	july 2021	DATE
dpc-1881	18	2	2021	CARDINAL
dpc-1881	20	1	medicina di precisione nelle	PERSON
dpc-1881	20	2	university of turin	ORG
dpc-1881	23	1	p.q	PERSON
dpc-1881	23	2	p.f.	GPE
dpc-1881	24	1	s.r and m.t.f	ORG
dpc-1881	25	1	md	GPE
dpc-1881	25	2	23, 10126	CARDINAL
dpc-1881	27	1	24 months	DATE
dpc-1881	27	2	5-year	DATE
dpc-1881	27	3	35-40%	PERCENT
dpc-1881	28	1	italian	NORP
dpc-1881	28	2	3	CARDINAL
dpc-1881	29	1	first	ORDINAL
dpc-1881	29	2	pembrolizumab	PERSON
dpc-1881	29	3	second	ORDINAL
dpc-1881	30	1	the dpc journal special	ORG
dpc-1881	30	2	today	DATE
dpc-1881	31	1	h. peter soyer	PERSON
dpc-1881	31	2	md	GPE
dpc-1881	32	1	the university of queensland diamantina institute	ORG
dpc-1881	32	2	alexandra hospital prof	PERSON
dpc-1881	33	1	paola queirolo	PERSON
dpc-1881	33	2	md	GPE
dpc-1881	33	3	the “divisione di oncologia medica del melanoma	ORG
dpc-1881	33	4	istituto europeo di oncologia	PERSON
dpc-1881	33	5	2	CARDINAL
dpc-1881	35	1	8th	ORDINAL
dpc-1881	35	2	american joint committee	ORG
dpc-1881	35	3	2018	DATE
dpc-1881	35	4	1	CARDINAL
dpc-1881	38	1	bio)-chemotherapy	ORG
dpc-1881	38	2	korn et al	PERSON
dpc-1881	39	1	2	CARDINAL
dpc-1881	39	2	more than 2,000	CARDINAL
dpc-1881	39	3	1975	DATE
dpc-1881	39	4	42	CARDINAL
dpc-1881	40	1	1-year	DATE
dpc-1881	40	2	25.5%	PERCENT
dpc-1881	40	3	6.2 months	DATE
dpc-1881	40	4	the last 30 years	DATE
dpc-1881	41	1	24 months	DATE
dpc-1881	41	2	5-year	DATE
dpc-1881	41	3	35-40%	PERCENT
dpc-1881	41	4	3	CARDINAL
dpc-1881	43	1	approximately 50%	PERCENT
dpc-1881	44	1	4	CARDINAL
dpc-1881	45	1	5	CARDINAL
dpc-1881	46	1	italian	NORP
dpc-1881	46	2	3	CARDINAL
dpc-1881	46	3	vemurafenib	PERSON
dpc-1881	47	1	first	ORDINAL
dpc-1881	47	2	pembrolizumab	PERSON
dpc-1881	47	3	second	ORDINAL
dpc-1881	50	1	anti-mek	NORP
dpc-1881	51	1	2	CARDINAL
dpc-1881	51	2	first	ORDINAL
dpc-1881	52	1	69%	PERCENT
dpc-1881	52	2	53%	PERCENT
dpc-1881	53	1	11 months	DATE
dpc-1881	53	2	8.8 months	DATE
dpc-1881	53	3	25.1 months	DATE
dpc-1881	53	4	18.7 months	DATE
dpc-1881	54	1	6	CARDINAL
dpc-1881	55	1	6	CARDINAL
dpc-1881	56	1	64%	PERCENT
dpc-1881	56	2	51%	PERCENT
dpc-1881	57	1	8	CARDINAL
dpc-1881	58	1	26.1	CARDINAL
dpc-1881	62	1	2021;11(s1	CARDINAL
dpc-1881	62	2	e2021164s 3 to 17.8 months	DATE
dpc-1881	63	1	12.1 months	DATE
dpc-1881	63	2	7.3 months	DATE
dpc-1881	64	1	8	CARDINAL
dpc-1881	66	1	2	CARDINAL
dpc-1881	66	2	22 month	DATE
dpc-1881	66	3	563	CARDINAL
dpc-1881	66	4	5-year	DATE
dpc-1881	66	5	19%	PERCENT
dpc-1881	66	6	5-year	DATE
dpc-1881	66	7	34%	PERCENT
dpc-1881	67	1	19%	PERCENT
dpc-1881	67	2	71%	PERCENT
dpc-1881	67	3	5 years	DATE
dpc-1881	69	1	10	CARDINAL
dpc-1881	70	1	3-year	DATE
dpc-1881	72	1	66 mm	QUANTITY
dpc-1881	72	2	3-year	DATE
dpc-1881	72	3	42%	PERCENT
dpc-1881	72	4	11	CARDINAL
dpc-1881	74	1	one	CARDINAL
dpc-1881	76	1	12,13	CARDINAL
dpc-1881	78	1	509	CARDINAL
dpc-1881	79	1	3	CARDINAL
dpc-1881	79	2	months	DATE
dpc-1881	79	3	≥6 months	DATE
dpc-1881	79	4	12 months	DATE
dpc-1881	79	5	6 months	DATE
dpc-1881	80	1	14	CARDINAL
dpc-1881	81	1	cobimetinib	ORG
dpc-1881	81	2	3	CARDINAL
dpc-1881	81	3	495	CARDINAL
dpc-1881	81	4	v600	ORG
dpc-1881	82	1	68%	PERCENT
dpc-1881	82	2	45%	PERCENT
dpc-1881	82	3	pfs	PERSON
dpc-1881	82	4	9.9	CARDINAL
dpc-1881	82	5	6.2 months	DATE
dpc-1881	82	6	(9 months os	DATE
dpc-1881	82	7	81%	PERCENT
dpc-1881	82	8	73%	PERCENT
dpc-1881	83	1	15	CARDINAL
dpc-1881	84	1	14.2-month	DATE
dpc-1881	84	2	12.3 months	DATE
dpc-1881	84	3	7.2 months	DATE
dpc-1881	84	4	vemurafenib	PERSON
dpc-1881	85	1	22.3 months	DATE
dpc-1881	85	2	cobimetinib	ORG
dpc-1881	85	3	vemurafenib	PERSON
dpc-1881	85	4	17.4 months	DATE
dpc-1881	85	5	vemurafenib	PERSON
dpc-1881	86	1	vemurafenib	PERSON
dpc-1881	86	2	16	CARDINAL
dpc-1881	87	1	third	ORDINAL
dpc-1881	87	2	anti-mek	NORP
dpc-1881	87	3	columbus	GPE
dpc-1881	88	1	columbus	GPE
dpc-1881	88	2	2	CARDINAL
dpc-1881	89	1	1	CARDINAL
dpc-1881	89	2	1:1:1	CARDINAL
dpc-1881	89	3	450	CARDINAL
dpc-1881	89	4	daily	DATE
dpc-1881	89	5	45	CARDINAL
dpc-1881	89	6	daily	DATE
dpc-1881	89	7	300	CARDINAL
dpc-1881	89	8	once	ORDINAL
dpc-1881	89	9	daily	DATE
dpc-1881	89	10	960	CARDINAL
dpc-1881	89	11	daily	DATE
dpc-1881	89	12	vemurafenib	ORG
dpc-1881	90	1	2	CARDINAL
dpc-1881	90	2	300	CARDINAL
dpc-1881	90	3	daily	DATE
dpc-1881	90	4	daily	DATE
dpc-1881	90	5	300	CARDINAL
dpc-1881	90	6	daily	DATE
dpc-1881	91	1	3-year	DATE
dpc-1881	91	2	33.6 months	DATE
dpc-1881	91	3	16.9 months	DATE
dpc-1881	91	4	vemurafenib	PERSON
dpc-1881	91	5	17	CARDINAL
dpc-1881	91	6	18	CARDINAL
dpc-1881	92	1	14.9 months	DATE
dpc-1881	92	2	7.3 months	DATE
dpc-1881	93	1	63%	PERCENT
dpc-1881	93	2	51%	PERCENT
dpc-1881	93	3	40%	PERCENT
dpc-1881	94	1	1.8 months	DATE
dpc-1881	95	1	3	CARDINAL
dpc-1881	95	2	more than 5%	PERCENT
dpc-1881	95	3	9%	PERCENT
dpc-1881	95	4	7%	PERCENT
dpc-1881	95	5	6%	PERCENT
dpc-1881	96	1	cd80 (b7-1	PRODUCT
dpc-1881	96	2	cd86	PRODUCT
dpc-1881	97	1	cd28	ORG
dpc-1881	97	2	b7-1	PRODUCT
dpc-1881	97	3	19	CARDINAL
dpc-1881	98	1	b7-1/2	PRODUCT
dpc-1881	100	1	4	CARDINAL
dpc-1881	101	1	±	CARDINAL
dpc-1881	101	2	100	CARDINAL
dpc-1881	102	1	ipilimumab	PERSON
dpc-1881	102	2	10.1 months	DATE
dpc-1881	102	3	6.4 months	DATE
dpc-1881	103	1	20	CARDINAL
dpc-1881	104	1	10 mg/kg	QUANTITY
dpc-1881	104	2	850 mg/sqm	QUANTITY
dpc-1881	104	3	850 mg/sqm	QUANTITY
dpc-1881	104	4	11.2 months	DATE
dpc-1881	104	5	9.1 months	DATE
dpc-1881	105	1	21	CARDINAL
dpc-1881	105	2	ipilimumab	PERSON
dpc-1881	105	3	1.861	CARDINAL
dpc-1881	105	4	10	CARDINAL
dpc-1881	105	5	2	CARDINAL
dpc-1881	105	6	up to	CARDINAL
dpc-1881	105	7	10-year	DATE
dpc-1881	105	8	around 3 years	DATE
dpc-1881	106	1	3-year	DATE
dpc-1881	106	2	22%	PERCENT
dpc-1881	106	3	26%	PERCENT
dpc-1881	106	4	20%	PERCENT
dpc-1881	106	5	22	CARDINAL
dpc-1881	107	1	eap	ORG
dpc-1881	107	2	italy	GPE
dpc-1881	107	3	23	CARDINAL
dpc-1881	108	1	24	CARDINAL
dpc-1881	110	1	two	CARDINAL
dpc-1881	110	2	pembrolizumab	PERSON
dpc-1881	111	1	066	CARDINAL
dpc-1881	111	2	first	ORDINAL
dpc-1881	112	1	418	CARDINAL
dpc-1881	112	2	1:1	CARDINAL
dpc-1881	113	1	40%	PERCENT
dpc-1881	113	2	13.9%	PERCENT
dpc-1881	113	3	1-year	DATE
dpc-1881	113	4	72.9%	PERCENT
dpc-1881	113	5	42.1%	PERCENT
dpc-1881	114	1	11.7%	PERCENT
dpc-1881	114	2	17.6%	PERCENT
dpc-1881	114	3	25	CARDINAL
dpc-1881	115	1	5-year	DATE
dpc-1881	115	2	26	CARDINAL
dpc-1881	115	3	orr	PERSON
dpc-1881	115	4	42%	PERCENT
dpc-1881	115	5	14%	PERCENT
dpc-1881	116	1	fiveyear	PERSON
dpc-1881	116	2	39%	PERCENT
dpc-1881	116	3	17%	PERCENT
dpc-1881	116	4	28% and 3%	PERCENT
dpc-1881	117	1	20%	PERCENT
dpc-1881	117	2	88%	PERCENT
dpc-1881	117	3	37	CARDINAL
dpc-1881	117	4	42	DATE
dpc-1881	117	5	5-year	DATE
dpc-1881	118	1	037	CARDINAL
dpc-1881	118	2	2:1	CARDINAL
dpc-1881	118	3	3 mg/kg	QUANTITY
dpc-1881	119	1	27	CARDINAL
dpc-1881	121	1	first	ORDINAL
dpc-1881	121	2	120	CARDINAL
dpc-1881	121	3	47	CARDINAL
dpc-1881	121	4	31.7%	PERCENT
dpc-1881	121	5	10.6%	PERCENT
dpc-1881	122	1	2018	DATE
dpc-1881	122	2	28	CARDINAL
dpc-1881	122	3	27%	PERCENT
dpc-1881	122	4	10%	PERCENT
dpc-1881	122	5	32	CARDINAL
dpc-1881	122	6	13 months	DATE
dpc-1881	122	7	icc	DATE
dpc-1881	123	1	3	CARDINAL
dpc-1881	123	2	4	CARDINAL
dpc-1881	123	3	14%	PERCENT
dpc-1881	123	4	34%	PERCENT
dpc-1881	124	1	16 months	DATE
dpc-1881	124	2	14 months	DATE
dpc-1881	125	1	3	CARDINAL
dpc-1881	125	2	834	CARDINAL
dpc-1881	125	3	10 mg/kg	QUANTITY
dpc-1881	125	4	4	CARDINAL
dpc-1881	125	5	3 mg/kg	QUANTITY
dpc-1881	126	1	6-months	DATE
dpc-1881	126	2	47.3%	PERCENT
dpc-1881	126	3	2 weeks	DATE
dpc-1881	126	4	46.4%	PERCENT
dpc-1881	126	5	3 weeks	DATE
dpc-1881	126	6	26.5%	PERCENT
dpc-1881	127	1	1-year	DATE
dpc-1881	127	2	74.1%	PERCENT
dpc-1881	127	3	68.4%	PERCENT
dpc-1881	127	4	58.2%	PERCENT
dpc-1881	128	1	pembrolizumab	PERSON
dpc-1881	128	2	2 or 3 weeks	DATE
dpc-1881	129	1	3–5	CARDINAL
dpc-1881	129	2	13.3%	PERCENT
dpc-1881	129	3	10.1%	PERCENT
dpc-1881	130	1	29	CARDINAL
dpc-1881	131	1	5-year	DATE
dpc-1881	131	2	32.7 months	DATE
dpc-1881	131	3	15.9 months	DATE
dpc-1881	132	1	8.4 months	DATE
dpc-1881	132	2	3.4 months	DATE
dpc-1881	132	3	30	CARDINAL
dpc-1881	133	1	pembrolizumab	PERSON
dpc-1881	133	2	24 months	DATE
dpc-1881	134	1	34·2 months	DATE
dpc-1881	134	2	24-month	DATE
dpc-1881	134	3	103	CARDINAL
dpc-1881	134	4	78.4%	PERCENT
dpc-1881	134	5	36-month	DATE
dpc-1881	134	6	93.8%	PERCENT
dpc-1881	135	1	24-month	DATE
dpc-1881	135	2	85.4%	PERCENT
dpc-1881	135	3	82.3%	PERCENT
dpc-1881	135	4	only 39.9%	PERCENT
dpc-1881	136	1	2 years	DATE
dpc-1881	137	1	keynote-002	ORG
dpc-1881	137	2	pembrolizumab 2 mg/kg	LAW
dpc-1881	137	3	10 mg/kg	QUANTITY
dpc-1881	140	1	180	CARDINAL
dpc-1881	140	2	pembrolizumab 2 mg/kg	LAW
dpc-1881	140	3	181	CARDINAL
dpc-1881	140	4	179	CARDINAL
dpc-1881	141	1	6-month	DATE
dpc-1881	141	2	34%	PERCENT
dpc-1881	141	3	38%	PERCENT
dpc-1881	141	4	the 10 mg/kg	QUANTITY
dpc-1881	141	5	16%	PERCENT
dpc-1881	141	6	31	CARDINAL
dpc-1881	142	1	5-year	DATE
dpc-1881	142	2	22%	PERCENT
dpc-1881	142	3	28%	PERCENT
dpc-1881	142	4	4%	PERCENT
dpc-1881	142	5	pembrolizumab	PERSON
dpc-1881	143	1	32	CARDINAL
dpc-1881	143	2	173	CARDINAL
dpc-1881	144	1	069	CARDINAL
dpc-1881	145	1	24.5 months	DATE
dpc-1881	145	2	two-year	DATE
dpc-1881	145	3	63.8%	PERCENT
dpc-1881	145	4	53.6%	PERCENT
dpc-1881	146	1	61%	PERCENT
dpc-1881	146	2	11%	PERCENT
dpc-1881	146	3	0.001	CARDINAL
dpc-1881	147	1	22%	PERCENT
dpc-1881	147	2	first	ORDINAL
dpc-1881	147	3	33	CARDINAL
dpc-1881	148	1	067	CARDINAL
dpc-1881	149	1	34,35	CARDINAL
dpc-1881	149	2	one	CARDINAL
dpc-1881	149	3	nivolumab	PERSON
dpc-1881	149	4	1 mg per kilogram	QUANTITY
dpc-1881	149	5	3 mg per kilogram	QUANTITY
dpc-1881	149	6	every 3 weeks	DATE
dpc-1881	149	7	4	CARDINAL
dpc-1881	149	8	nivolumab	PERSON
dpc-1881	149	9	3 mg per kilogram	QUANTITY
dpc-1881	149	10	nivolumab	PERSON
dpc-1881	149	11	3 mg per kilogram	QUANTITY
dpc-1881	149	12	3 mg per kilogram	QUANTITY
dpc-1881	149	13	four	CARDINAL
dpc-1881	150	1	2	CARDINAL
dpc-1881	150	2	pfs	PERSON
dpc-1881	151	1	945	CARDINAL
dpc-1881	152	1	11.5 months	DATE
dpc-1881	152	2	95%	PERCENT
dpc-1881	152	3	ci 8.9-16.7	PERSON
dpc-1881	152	4	6.9 months	DATE
dpc-1881	152	5	95%	PERCENT
dpc-1881	152	6	4.3-9.5	CARDINAL
dpc-1881	152	7	2.9 months	DATE
dpc-1881	152	8	95%	PERCENT
dpc-1881	152	9	2.8-3.4	CARDINAL
dpc-1881	153	1	58%	PERCENT
dpc-1881	153	2	0.42	CARDINAL
dpc-1881	153	3	99.5%	PERCENT
dpc-1881	153	4	0.31-0.57	CARDINAL
dpc-1881	154	1	57.6%	PERCENT
dpc-1881	154	2	95%	PERCENT
dpc-1881	154	3	52.0-63.2	CARDINAL
dpc-1881	154	4	43.7%	PERCENT
dpc-1881	154	5	95%	PERCENT
dpc-1881	154	6	38.1-49.3	CARDINAL
dpc-1881	154	7	19%	PERCENT
dpc-1881	154	8	95%	PERCENT
dpc-1881	154	9	14.9-23.8	CARDINAL
dpc-1881	155	1	11.5%	PERCENT
dpc-1881	155	2	8.9%	PERCENT
dpc-1881	155	3	2.2%	PERCENT
dpc-1881	156	1	more than 5%	PERCENT
dpc-1881	156	2	at least 100	CARDINAL
dpc-1881	156	3	14.0 months	DATE
dpc-1881	157	1	11.2 months	DATE
dpc-1881	157	2	95%	PERCENT
dpc-1881	157	3	8.0	CARDINAL
dpc-1881	157	4	5.3 months	DATE
dpc-1881	157	5	95%	PERCENT
dpc-1881	157	6	2.8	CARDINAL
dpc-1881	159	1	5 years	DATE
dpc-1881	159	2	52%	PERCENT
dpc-1881	159	3	44%	PERCENT
dpc-1881	159	4	26%	PERCENT
dpc-1881	160	1	36	CARDINAL
dpc-1881	161	1	3	CARDINAL
dpc-1881	161	2	4	CARDINAL
dpc-1881	161	3	59%	PERCENT
dpc-1881	161	4	23%	PERCENT
dpc-1881	161	5	28%	PERCENT
dpc-1881	162	1	europe	LOC
dpc-1881	162	2	ema	ORG
dpc-1881	162	3	may 2016	DATE
dpc-1881	164	1	11	CARDINAL
dpc-1881	164	2	13	DATE
dpc-1881	164	3	the pi3k/akt	ORG
dpc-1881	168	1	37	CARDINAL
dpc-1881	170	1	around 20% and 30%	PERCENT
dpc-1881	171	1	6	CARDINAL
dpc-1881	173	1	78	CARDINAL
dpc-1881	173	2	dcr	ORG
dpc-1881	173	3	21.8%	PERCENT
dpc-1881	173	4	60.3%	PERCENT
dpc-1881	174	1	13.1	CARDINAL
dpc-1881	174	2	40	CARDINAL
dpc-1881	175	1	first	ORDINAL
dpc-1881	176	1	nras mutant	PERSON
dpc-1881	176	2	nras	FAC
dpc-1881	176	3	12	CARDINAL
dpc-1881	176	4	13	DATE
dpc-1881	176	5	61	CARDINAL
dpc-1881	176	6	15-20 %	PERCENT
dpc-1881	177	1	italian	NORP
dpc-1881	177	2	nras	ORG
dpc-1881	178	1	331	CARDINAL
dpc-1881	178	2	first	ORDINAL
dpc-1881	178	3	162	CARDINAL
dpc-1881	178	4	169	CARDINAL
dpc-1881	180	1	41	CARDINAL
dpc-1881	181	1	anti-mek	NORP
dpc-1881	183	1	269	CARDINAL
dpc-1881	183	2	133	CARDINAL
dpc-1881	184	1	2.8 months	DATE
dpc-1881	184	2	1.5	CARDINAL
dpc-1881	186	1	5.5 months	DATE
dpc-1881	186	2	42	CARDINAL
dpc-1881	187	1	4 months	DATE
dpc-1881	188	1	43	CARDINAL
dpc-1881	188	2	2	CARDINAL
dpc-1881	188	3	4	CARDINAL
dpc-1881	189	1	44% to 59%	PERCENT
dpc-1881	189	2	19%	PERCENT
dpc-1881	189	3	12 months	DATE
dpc-1881	190	1	dabrafenib	PERSON
dpc-1881	190	2	brafv600	GPE
dpc-1881	190	3	47	CARDINAL
dpc-1881	191	1	pembrolizumab	PERSON
dpc-1881	191	2	16% to 25%	PERCENT
dpc-1881	191	3	around 40% -50%	PERCENT
dpc-1881	192	1	45	CARDINAL
dpc-1881	193	1	3	CARDINAL
dpc-1881	193	2	46% to 55%	PERCENT
dpc-1881	194	1	abc	ORG
dpc-1881	194	2	2	CARDINAL
dpc-1881	194	3	+ ipilimumab	GPE
dpc-1881	195	1	third	ORDINAL
dpc-1881	196	1	51%	PERCENT
dpc-1881	196	2	20%	PERCENT
dpc-1881	196	3	6%	PERCENT
dpc-1881	197	1	59%	PERCENT
dpc-1881	197	2	21%	PERCENT
dpc-1881	198	1	pfs	PERSON
dpc-1881	198	2	43%	PERCENT
dpc-1881	198	3	3 years	DATE
dpc-1881	198	4	15% and 6%	PERCENT
dpc-1881	199	1	48	CARDINAL
dpc-1881	200	1	second	ORDINAL
dpc-1881	200	2	the ipi nivo combination	ORG
dpc-1881	200	3	204	CARDINAL
dpc-1881	200	4	75	CARDINAL
dpc-1881	200	5	55%	PERCENT
dpc-1881	200	6	53%	PERCENT
dpc-1881	200	7	2.8 months	DATE
dpc-1881	200	8	49	CARDINAL
dpc-1881	201	1	third	ORDINAL
dpc-1881	201	2	3	CARDINAL
dpc-1881	201	3	three	CARDINAL
dpc-1881	202	1	44%	PERCENT
dpc-1881	202	2	36%	PERCENT
dpc-1881	202	3	4 years	DATE
dpc-1881	202	4	41%	PERCENT
dpc-1881	202	5	4 years	DATE
dpc-1881	202	6	50	CARDINAL
dpc-1881	203	1	51	CARDINAL
dpc-1881	204	1	e2021164s 7	DATE
dpc-1881	205	1	2-fold	CARDINAL
dpc-1881	206	1	2	CARDINAL
dpc-1881	207	1	52	CARDINAL
dpc-1881	208	1	keynote-022	PERSON
dpc-1881	208	2	53	CARDINAL
dpc-1881	208	3	first	ORDINAL
dpc-1881	208	4	120	CARDINAL
dpc-1881	209	1	16.9	CARDINAL
dpc-1881	209	2	10.7 months	DATE
dpc-1881	209	3	36 months	DATE
dpc-1881	209	4	25.1 months	DATE
dpc-1881	209	5	12.1 months	DATE
dpc-1881	210	1	58.3%	PERCENT
dpc-1881	210	2	3-5	CARDINAL
dpc-1881	210	3	26.7%	PERCENT
dpc-1881	211	1	3	CARDINAL
dpc-1881	211	2	vemurafenib	PERSON
dpc-1881	211	3	vemurafenib	PERSON
dpc-1881	211	4	cobimetinib	ORG
dpc-1881	212	1	514	CARDINAL
dpc-1881	213	1	18.9 month	DATE
dpc-1881	213	2	pfs	PERSON
dpc-1881	213	3	15.1	CARDINAL
dpc-1881	213	4	10.6 months	DATE
dpc-1881	214	1	1	CARDINAL
dpc-1881	214	2	3	CARDINAL
dpc-1881	215	1	months	DATE
dpc-1881	215	2	months	DATE
dpc-1881	215	3	95%	PERCENT
dpc-1881	215	4	69	CARDINAL
dpc-1881	215	5	69.6	CARDINAL
dpc-1881	215	6	12.3	CARDINAL
dpc-1881	215	7	12.6	CARDINAL
dpc-1881	215	8	33.6	CARDINAL
dpc-1881	215	9	cobrim4	ORG
dpc-1881	216	1	vemurafenib combi-v5	PERSON
dpc-1881	216	2	vemurafenib colombus encorafenib	ORG
dpc-1881	216	3	2	CARDINAL
dpc-1881	217	1	the 7th week	DATE
dpc-1881	218	1	3 months	DATE
dpc-1881	218	2	8	CARDINAL
dpc-1881	219	1	fda	ORG
dpc-1881	219	2	keynote-022	GPE
dpc-1881	220	1	3	CARDINAL
dpc-1881	220	2	79%	PERCENT
dpc-1881	220	3	73%	PERCENT
dpc-1881	220	4	13%	PERCENT
dpc-1881	220	5	16%	PERCENT
dpc-1881	221	1	54	CARDINAL
dpc-1881	222	1	3	CARDINAL
dpc-1881	222	2	55	CARDINAL
dpc-1881	223	1	532	CARDINAL
dpc-1881	224	1	16.2	CARDINAL
dpc-1881	224	2	12 months	DATE
dpc-1881	225	1	69%	PERCENT
dpc-1881	225	2	64%	PERCENT
dpc-1881	226	1	3	CARDINAL
dpc-1881	226	2	55%	PERCENT
dpc-1881	226	3	33%	PERCENT
dpc-1881	229	1	3	CARDINAL
dpc-1881	231	1	40%nivolumab	CARDINAL
dpc-1881	231	2	pembrolizumab	PERSON
dpc-1881	231	3	ipi	ORG
dpc-1881	231	4	ipi	ORG
dpc-1881	231	5	066	CARDINAL
dpc-1881	231	6	037	CARDINAL
dpc-1881	231	7	002	CARDINAL
dpc-1881	231	8	006	CARDINAL
dpc-1881	231	9	067 31,3% % cr 7,6%	PERCENT
dpc-1881	231	10	3,3%	PERCENT
dpc-1881	231	11	2-3%	PERCENT
dpc-1881	231	12	12-13%	PERCENT
dpc-1881	231	13	21,3%58,3%	PERCENT
dpc-1881	231	14	36-37%	PERCENT
dpc-1881	231	15	29-31%	DATE
dpc-1881	231	16	4	CARDINAL
dpc-1881	233	1	1 year	DATE
dpc-1881	236	1	e2021164s 9	DATE
dpc-1881	236	2	1-year	DATE
dpc-1881	236	3	25%	PERCENT
dpc-1881	236	4	6 months	DATE
dpc-1881	237	1	2	CARDINAL
dpc-1881	237	2	5-year	DATE
dpc-1881	237	3	35%	PERCENT
dpc-1881	237	4	24 months	DATE
dpc-1881	237	5	italian	NORP
dpc-1881	237	6	european	NORP
dpc-1881	237	7	american	NORP
dpc-1881	238	1	5 years	DATE
dpc-1881	238	2	65%	PERCENT
dpc-1881	240	1	daily	DATE
dpc-1881	243	1	1	CARDINAL
dpc-1881	243	2	gershenwald je	PERSON
dpc-1881	243	3	hess kr	PERSON
dpc-1881	244	1	the american joint committee	ORG
dpc-1881	245	1	the american joint committee	ORG
dpc-1881	245	2	eighth	ORDINAL
dpc-1881	246	1	j clin	PERSON
dpc-1881	247	1	2017;67(6):472-492	CARDINAL
dpc-1881	248	1	10.3322/	CARDINAL
dpc-1881	249	1	29028110	DATE
dpc-1881	250	1	2	CARDINAL
dpc-1881	250	2	korn el	PERSON
dpc-1881	250	3	liu py	PERSON
dpc-1881	250	4	lee sj	PERSON
dpc-1881	250	5	chapman ja	PERSON
dpc-1881	251	1	ii cooperative group trials	ORG
dpc-1881	252	1	j clin	PERSON
dpc-1881	252	2	oncol 2008;26	DATE
dpc-1881	252	3	527	CARDINAL
dpc-1881	253	1	10.1200	CARDINAL
dpc-1881	254	1	18235113	DATE
dpc-1881	255	1	3	CARDINAL
dpc-1881	255	2	ugurel s	ORG
dpc-1881	255	3	ascierto pa	GPE
dpc-1881	255	4	2019	DATE
dpc-1881	257	1	2020	DATE
dpc-1881	258	1	130:126-138	DATE
dpc-1881	259	1	10.1016	CARDINAL
dpc-1881	260	1	32179447	DATE
dpc-1881	261	1	4	CARDINAL
dpc-1881	261	2	atlas network	ORG
dpc-1881	263	1	2015	CARDINAL
dpc-1881	263	2	161:1681-96	DATE
dpc-1881	264	1	10.1016	CARDINAL
dpc-1881	265	1	26091043	CARDINAL
dpc-1881	266	1	5	CARDINAL
dpc-1881	266	2	keilholz u	PERSON
dpc-1881	266	3	ascierto pa	GPE
dpc-1881	266	4	the esmo guidelines committee	ORG
dpc-1881	267	1	ann oncol	PERSON
dpc-1881	268	1	2020;31(11):1435-1448	CARDINAL
dpc-1881	269	1	10.1016	CARDINAL
dpc-1881	269	2	j. annonc.2020.07.004	WORK_OF_ART
dpc-1881	270	1	32763453	CARDINAL
dpc-1881	271	1	6	CARDINAL
dpc-1881	271	2	gogas h	ORG
dpc-1881	271	3	3	CARDINAL
dpc-1881	272	1	lancet	ORG
dpc-1881	273	1	2015	CARDINAL
dpc-1881	273	2	386(9992):444	CARDINAL
dpc-1881	274	1	10.1016/	CARDINAL
dpc-1881	275	1	schadendorf	PERSON
dpc-1881	275	2	amonkar mm	PERSON
dpc-1881	275	3	v600	ORG
dpc-1881	277	1	2015;51(7):833-40	CARDINAL
dpc-1881	278	1	10.1016	CARDINAL
dpc-1881	279	1	pmid	PERSON
dpc-1881	279	2	25794603.	DATE
dpc-1881	280	1	robert c	PERSON
dpc-1881	280	2	schachter j	PERSON
dpc-1881	282	1	2015;372(1):30-9	DATE
dpc-1881	282	2	10.1056	CARDINAL
dpc-1881	283	1	25399551	DATE
dpc-1881	284	1	9	CARDINAL
dpc-1881	285	1	grob jj	PERSON
dpc-1881	285	2	amonkar mm	PERSON
dpc-1881	285	3	3	CARDINAL
dpc-1881	286	1	lancet	ORG
dpc-1881	286	2	oncol.	DATE
dpc-1881	287	1	2015	CARDINAL
dpc-1881	287	2	16(13):1389-98	CARDINAL
dpc-1881	288	1	10.1016	CARDINAL
dpc-1881	288	2	2045(15)00087-x. 10	QUANTITY
dpc-1881	289	1	robert c	PERSON
dpc-1881	289	2	grob jj	PERSON
dpc-1881	289	3	five-year	DATE
dpc-1881	290	1	2019	CARDINAL
dpc-1881	290	2	381(7):626	CARDINAL
dpc-1881	290	3	636	CARDINAL
dpc-1881	291	1	10.1056	CARDINAL
dpc-1881	292	1	31166680	DATE
dpc-1881	293	1	11	CARDINAL
dpc-1881	294	1	schadendorf	PERSON
dpc-1881	295	1	three-year	DATE
dpc-1881	295	2	3	CARDINAL
dpc-1881	297	1	2017	CARDINAL
dpc-1881	297	2	82:45-55	DATE
dpc-1881	298	1	10.1016	CARDINAL
dpc-1881	298	2	j. ejca.2017.05.033	WORK_OF_ART
dpc-1881	299	1	pmid	PERSON
dpc-1881	299	2	28648698	DATE
dpc-1881	300	1	12	CARDINAL
dpc-1881	301	1	chan mm	PERSON
dpc-1881	301	2	haydu le	ORG
dpc-1881	301	3	menzies	PERSON
dpc-1881	304	1	2014,120	CARDINAL
dpc-1881	304	2	3142–3153	DATE
dpc-1881	304	3	10.1002	CARDINAL
dpc-1881	304	4	24985732	CARDINAL
dpc-1881	305	1	13	CARDINAL
dpc-1881	306	1	hassel jc	PERSON
dpc-1881	306	2	german	NORP
dpc-1881	309	1	2018,7	CARDINAL
dpc-1881	309	2	95–104	GPE
dpc-1881	309	3	10.1002	CARDINAL
dpc-1881	310	1	29266761	DATE
dpc-1881	311	1	14	CARDINAL
dpc-1881	312	1	atkinson	PERSON
dpc-1881	312	2	aglietta m	PERSON
dpc-1881	314	1	eado2019	GPE
dpc-1881	314	2	paris	GPE
dpc-1881	315	1	15	CARDINAL
dpc-1881	316	1	larkin j	PERSON
dpc-1881	316	2	ascierto pa	GPE
dpc-1881	316	3	vemurafenib	PERSON
dpc-1881	317	1	2014	DATE
dpc-1881	317	2	371	CARDINAL
dpc-1881	317	3	1867-76	DATE
dpc-1881	318	1	10.1056/nejmoa1408868	QUANTITY
dpc-1881	319	1	25265494	DATE
dpc-1881	320	1	16	CARDINAL
dpc-1881	321	1	ascierto pa	GPE
dpc-1881	321	2	mcarthur ga	GPE
dpc-1881	321	3	cobimetinib	ORG
dpc-1881	321	4	3	CARDINAL
dpc-1881	323	1	2016;17(9):1248-60	CARDINAL
dpc-1881	324	1	10.1016	CARDINAL
dpc-1881	324	2	2045(16)30122-x. 17	CARDINAL
dpc-1881	325	1	dummer r	ORG
dpc-1881	325	2	ascierto pa	GPE
dpc-1881	325	3	gogas hj	PERSON
dpc-1881	325	4	encorafenib	PERSON
dpc-1881	325	5	vemurafenib	PERSON
dpc-1881	325	6	10	CARDINAL
dpc-1881	326	1	columbus	GPE
dpc-1881	326	2	3	CARDINAL
dpc-1881	328	1	2018;19(5):603-615	CARDINAL
dpc-1881	329	1	10.1016	CARDINAL
dpc-1881	329	2	2045(18)30142	CARDINAL
dpc-1881	329	3	18	CARDINAL
dpc-1881	330	1	dummer r	ORG
dpc-1881	330	2	ascierto pa	GPE
dpc-1881	330	3	gogas hj	PERSON
dpc-1881	331	1	vemurafenib	PERSON
dpc-1881	331	2	columbus	GPE
dpc-1881	331	3	3	CARDINAL
dpc-1881	333	1	2018	DATE
dpc-1881	333	2	19(10):1315	CARDINAL
dpc-1881	334	1	doi:10.1016	GPE
dpc-1881	335	1	callahan mk	PERSON
dpc-1881	335	2	flaherty cr	PERSON
dpc-1881	335	3	postow ma	PERSON
dpc-1881	336	1	2016	CARDINAL
dpc-1881	336	2	167:231-50	DATE
dpc-1881	337	1	10.1007/978-3-319-22539-5_9	CARDINAL
dpc-1881	338	1	26601865	DATE
dpc-1881	339	1	20	CARDINAL
dpc-1881	340	1	hodi fs	PERSON
dpc-1881	340	2	o’day	DATE
dpc-1881	340	3	mcdermott df	PERSON
dpc-1881	342	1	2010	DATE
dpc-1881	343	1	363:711–23	CARDINAL
dpc-1881	343	2	10.1056	CARDINAL
dpc-1881	344	1	20525992	DATE
dpc-1881	346	1	robert c	PERSON
dpc-1881	346	2	thomas l	PERSON
dpc-1881	346	3	ipilimumab	PERSON
dpc-1881	347	1	j med.	PERSON
dpc-1881	348	1	2011	DATE
dpc-1881	348	2	364:2517–26	CARDINAL
dpc-1881	348	3	10.1056	CARDINAL
dpc-1881	349	1	21639810	DATE
dpc-1881	350	1	22	CARDINAL
dpc-1881	351	1	schadendorf	PERSON
dpc-1881	351	2	hodi fs	PERSON
dpc-1881	351	3	robert c	PERSON
dpc-1881	352	1	j clin oncol	PERSON
dpc-1881	353	1	2015	CARDINAL
dpc-1881	354	1	33:1889–94	CARDINAL
dpc-1881	355	1	10.1200	CARDINAL
dpc-1881	356	1	25667295	DATE
dpc-1881	357	1	23	CARDINAL
dpc-1881	358	1	ascierto pa	GPE
dpc-1881	358	2	simeone e	GPE
dpc-1881	358	3	sileni vc	PERSON
dpc-1881	359	1	3 mg/kg	QUANTITY
dpc-1881	360	1	2014	DATE
dpc-1881	360	2	12:116	CARDINAL
dpc-1881	361	1	10.1186/1479-5876-12	CARDINAL
dpc-1881	362	1	24885479	CARDINAL
dpc-1881	363	1	24	CARDINAL
dpc-1881	364	1	queirolo p	PERSON
dpc-1881	364	2	boutros	PRODUCT
dpc-1881	364	3	tanda e	ORG
dpc-1881	366	1	2019	DATE
dpc-1881	366	2	59:290-297	CARDINAL
dpc-1881	367	1	31430555	CARDINAL
dpc-1881	368	1	25	CARDINAL
dpc-1881	369	1	robert c	PERSON
dpc-1881	369	2	brady	PERSON
dpc-1881	369	3	nivolumab	PERSON
dpc-1881	370	1	2014	DATE
dpc-1881	370	2	372:320–30	DATE
dpc-1881	371	1	10.1056	CARDINAL
dpc-1881	372	1	25399552	CARDINAL
dpc-1881	373	1	26	CARDINAL
dpc-1881	374	1	robert c	PERSON
dpc-1881	374	2	brady	PERSON
dpc-1881	374	3	five-year	DATE
dpc-1881	375	1	j clin oncol	PERSON
dpc-1881	376	1	2020	DATE
dpc-1881	376	2	38(33):3937	CARDINAL
dpc-1881	376	3	3946	CARDINAL
dpc-1881	377	1	10.1200/	CARDINAL
dpc-1881	378	1	32997575	DATE
dpc-1881	379	1	27	CARDINAL
dpc-1881	380	1	weber j	PERSON
dpc-1881	380	2	nivolumab	PERSON
dpc-1881	380	3	037	CARDINAL
dpc-1881	380	4	3	CARDINAL
dpc-1881	381	1	oncol.	DATE
dpc-1881	382	1	2015	DATE
dpc-1881	382	2	84	CARDINAL
dpc-1881	383	1	10.1016	CARDINAL
dpc-1881	383	2	2045(15)70076-8	DATE
dpc-1881	384	1	larkin j	PERSON
dpc-1881	385	1	037	CARDINAL
dpc-1881	386	1	j clin oncol	PERSON
dpc-1881	387	1	2018	DATE
dpc-1881	387	2	36(4):383	CARDINAL
dpc-1881	388	1	10.1200/jco.2016.71.8023.	MONEY
dpc-1881	389	1	28671856	DATE
dpc-1881	390	1	29	CARDINAL
dpc-1881	391	1	robert c	PERSON
dpc-1881	391	2	pembrolizumab versus ipilimumab	PERSON
dpc-1881	392	1	2015	CARDINAL
dpc-1881	392	2	372:2521	CARDINAL
dpc-1881	392	3	32	CARDINAL
dpc-1881	393	1	10.1056	CARDINAL
dpc-1881	394	1	25891173	DATE
dpc-1881	395	1	30	CARDINAL
dpc-1881	396	1	robert c	PERSON
dpc-1881	396	2	ribas	PERSON
dpc-1881	396	3	pembrolizumab versus ipilimumab	PERSON
dpc-1881	396	4	5-year	DATE
dpc-1881	396	5	3	CARDINAL
dpc-1881	398	1	2019;20(9):1239-1251	DATE
dpc-1881	399	1	10.1016	CARDINAL
dpc-1881	400	1	ribas	PERSON
dpc-1881	400	2	pembrolizumab	PERSON
dpc-1881	400	3	keynote-002	ORG
dpc-1881	400	4	2	CARDINAL
dpc-1881	401	1	oncol.	DATE
dpc-1881	402	1	2015	CARDINAL
dpc-1881	403	1	16:908–18	CARDINAL
dpc-1881	404	1	10.1016	CARDINAL
dpc-1881	404	2	s14702045(15)00083-2	EVENT
dpc-1881	404	3	32	CARDINAL
dpc-1881	405	1	hamid o	PERSON
dpc-1881	407	1	2017	CARDINAL
dpc-1881	407	2	86:37-45	DATE
dpc-1881	408	1	10.1016	CARDINAL
dpc-1881	408	2	j. ejca.2017.07.022	PERSON
dpc-1881	409	1	28961465	DATE
dpc-1881	410	1	33	CARDINAL
dpc-1881	411	1	hodi fs	PERSON
dpc-1881	411	2	chesney j	ORG
dpc-1881	411	3	pavlick ac	GPE
dpc-1881	411	4	ipilimumab versus ipilimumab	PERSON
dpc-1881	411	5	2-year	DATE
dpc-1881	411	6	2	CARDINAL
dpc-1881	413	1	2016	CARDINAL
dpc-1881	413	2	17(11):1558-1568	CARDINAL
dpc-1881	414	1	10.1016	CARDINAL
dpc-1881	414	2	2045(16)30366-7	DATE
dpc-1881	414	3	34	CARDINAL
dpc-1881	415	1	postow ma	PERSON
dpc-1881	415	2	chesney j	PERSON
dpc-1881	415	3	pavlick ac	GPE
dpc-1881	415	4	nivolumab	PERSON
dpc-1881	415	5	ipilimumab versus ipilimumab	PERSON
dpc-1881	416	1	2015	CARDINAL
dpc-1881	417	1	372(21):2006-17	DATE
dpc-1881	418	1	10.1056	CARDINAL
dpc-1881	419	1	25891304	CARDINAL
dpc-1881	420	1	35	DATE
dpc-1881	421	1	larkin j	PERSON
dpc-1881	421	2	gonzalez	PERSON
dpc-1881	422	1	five-year	DATE
dpc-1881	423	1	2019	CARDINAL
dpc-1881	423	2	381(16):1535-1546	DATE
dpc-1881	424	1	10.1056/	CARDINAL
dpc-1881	425	1	31562797	CARDINAL
dpc-1881	426	1	36	CARDINAL
dpc-1881	426	2	mcdermott df	PERSON
dpc-1881	426	3	shah r	PERSON
dpc-1881	427	1	versus ipilimumab	PERSON
dpc-1881	429	1	2019;28(1):109	CARDINAL
dpc-1881	429	2	119	CARDINAL
dpc-1881	430	1	10.1007	CARDINAL
dpc-1881	431	1	30191365	DATE
dpc-1881	433	1	hodi fs	PERSON
dpc-1881	435	1	j clin oncol	PERSON
dpc-1881	437	1	10.1200	CARDINAL
dpc-1881	438	1	23775962	DATE
dpc-1881	439	1	38	DATE
dpc-1881	440	1	carvajal rd	PERSON
dpc-1881	440	2	antonescu cr	PERSON
dpc-1881	440	3	wolchok jd	PERSON
dpc-1881	442	1	2011	DATE
dpc-1881	443	1	305:23272334	CARDINAL
dpc-1881	443	2	10.1001	CARDINAL
dpc-1881	444	1	21642685	CARDINAL
dpc-1881	445	1	39	CARDINAL
dpc-1881	446	1	guo j	PERSON
dpc-1881	447	1	j clin	PERSON
dpc-1881	447	2	oncol.	DATE
dpc-1881	448	1	2011	DATE
dpc-1881	448	2	29:2904-9	DATE
dpc-1881	448	3	10.1200	CARDINAL
dpc-1881	449	1	21690468.	DATE
dpc-1881	451	1	wei x	PERSON
dpc-1881	451	2	mao l	PERSON
dpc-1881	453	1	2019;27(4):495-501	CARDINAL
dpc-1881	454	1	10.3727/096504018x15 331163433914	DATE
dpc-1881	455	1	30075827	CARDINAL
dpc-1881	456	1	41	CARDINAL
dpc-1881	457	1	guida m	PERSON
dpc-1881	458	1	italian	NORP
dpc-1881	459	1	nras	ORG
dpc-1881	459	2	italian	NORP
dpc-1881	460	1	2021	CARDINAL
dpc-1881	460	2	13(3):475	CARDINAL
dpc-1881	461	1	10.3390	CARDINAL
dpc-1881	462	1	33530579	CARDINAL
dpc-1881	463	1	42	DATE
dpc-1881	464	1	ascierto pa	GPE
dpc-1881	464	2	binimetinib versus	PERSON
dpc-1881	464	3	nras	NORP
dpc-1881	464	4	nemo	PRODUCT
dpc-1881	464	5	3	CARDINAL
dpc-1881	466	1	2017;18(4):435	CARDINAL
dpc-1881	467	1	10.1016	CARDINAL
dpc-1881	468	1	davies ma	PERSON
dpc-1881	468	2	liu p	PERSON
dpc-1881	468	3	mcintyre s	PERSON
dpc-1881	471	1	e2021164s 11	DATE
dpc-1881	472	1	2011;117(8):1687-96	DATE
dpc-1881	472	2	10.1002	CARDINAL
dpc-1881	473	1	20960525	DATE
dpc-1881	474	1	44	DATE
dpc-1881	475	1	merlo df	PERSON
dpc-1881	478	1	2014;24(1):61-7	DATE
dpc-1881	478	2	10.1097	CARDINAL
dpc-1881	479	1	24121190	DATE
dpc-1881	480	1	45	CARDINAL
dpc-1881	480	2	becco	PERSON
dpc-1881	481	1	gallo s	ORG
dpc-1881	483	1	10.3390	CARDINAL
dpc-1881	484	1	32575838	DATE
dpc-1881	485	1	46	DATE
dpc-1881	485	2	massi d. melanoma	PERSON
dpc-1881	487	1	2020;7(2):mmt44	CARDINAL
dpc-1881	488	1	10.2217/ mmt-2019-0021	DATE
dpc-1881	489	1	47	DATE
dpc-1881	490	1	davies ma	PERSON
dpc-1881	490	2	saiag	ORG
dpc-1881	490	3	robert c	PERSON
dpc-1881	490	4	dabrafenib	PERSON
dpc-1881	490	5	2	CARDINAL
dpc-1881	492	1	2017;18(7):863-873	CARDINAL
dpc-1881	493	1	10.1016	CARDINAL
dpc-1881	493	2	48	DATE
dpc-1881	494	1	atkinson	PERSON
dpc-1881	494	2	lo s	PERSON
dpc-1881	494	3	ipilimumab	PERSON
dpc-1881	494	4	2	CARDINAL
dpc-1881	496	1	2018;19(5):672-681	CARDINAL
dpc-1881	497	1	10.1016	CARDINAL
dpc-1881	497	2	49	DATE
dpc-1881	498	1	forsyth pa	GPE
dpc-1881	498	2	algazi	GPE
dpc-1881	501	1	2018;379(8):722-730	CARDINAL
dpc-1881	501	2	10.1056	CARDINAL
dpc-1881	502	1	pmid	PERSON
dpc-1881	502	2	30134131	DATE
dpc-1881	503	1	50	CARDINAL
dpc-1881	503	2	di giacomo am	PERSON
dpc-1881	503	3	chiarion sileni v	PERSON
dpc-1881	503	4	del vecchio m	ORG
dpc-1881	503	5	ipilimumab plusfotemustine	PERSON
dpc-1881	503	6	esmo 2020	EVENT
dpc-1881	504	1	10.1016/j.annonc.2020.08.1205	PERCENT
dpc-1881	505	1	51	DATE
dpc-1881	506	1	trojaniello c	ORG
dpc-1881	506	2	ascierto pa	GPE
dpc-1881	506	3	mek	ORG
dpc-1881	506	4	pd1/pd-l1 blockade	ORG
dpc-1881	507	1	curr opin	PERSON
dpc-1881	507	2	oncol 2021	DATE
dpc-1881	508	1	10.1097/	CARDINAL
dpc-1881	508	2	33399314	DATE
dpc-1881	509	1	52	DATE
dpc-1881	509	2	mandalà m	PERSON
dpc-1881	509	3	massi d. immunotolerance	PERSON
dpc-1881	510	1	handb exp pharmacol	ORG
dpc-1881	511	1	2018	DATE
dpc-1881	511	2	249:129-143	CARDINAL
dpc-1881	512	1	10.1007/164_2017_5	CARDINAL
dpc-1881	513	1	28238077	CARDINAL
dpc-1881	514	1	53	CARDINAL
dpc-1881	514	2	ferrucci	DATE
dpc-1881	514	3	di giacomo am	PERSON
dpc-1881	514	4	del vecchio m	ORG
dpc-1881	515	1	keynote-022	PERSON
dpc-1881	515	2	3	CARDINAL
dpc-1881	515	3	2	CARDINAL
dpc-1881	515	4	pembrolizumab	GPE
dpc-1881	516	1	2020;8	CARDINAL
dpc-1881	517	1	10.1136/jitc-2020-001806	MONEY
dpc-1881	518	1	33361337	DATE
dpc-1881	519	1	54	DATE
dpc-1881	519	2	gogas h	ORG
dpc-1881	519	3	atezolizumab	PERSON
dpc-1881	519	4	vemurafenib	PERSON
dpc-1881	519	5	first	ORDINAL
dpc-1881	519	6	braf(v600	ORG
dpc-1881	519	7	3	CARDINAL
dpc-1881	520	1	lancet	ORG
dpc-1881	521	1	2020	DATE
dpc-1881	521	2	13;395(10240):18351844	CARDINAL
dpc-1881	521	3	10.1016	CARDINAL
dpc-1881	522	1	nathan p	ORG
dpc-1881	523	1	lba43 spartalizumab	PERSON
dpc-1881	523	2	v600	ORG
dpc-1881	523	3	3	CARDINAL
dpc-1881	524	1	ann oncol 2020	PERSON
dpc-1881	525	1	doi:10.1016/j. annonc.2020.08.2273.	ORG
dpc-1881	526	1	56	CARDINAL
dpc-1881	527	1	associazione italiana di oncologia medica	ORG
dpc-1881	528	1	www.aiom.it 57	PERSON
dpc-1881	529	1	seth r	PERSON
dpc-1881	529	2	messersmith h	ORG
dpc-1881	529	3	kaur v	PERSON
dpc-1881	530	1	asco guideline	PERSON
dpc-1881	531	1	j clin oncol	PERSON
dpc-1881	532	1	2020	DATE
dpc-1881	532	2	38(33):3947-3970	DATE
dpc-1881	533	1	10.1200/jco.20.00198	DATE
dpc-1881	534	1	32228358	CARDINAL
dpc-1881	535	1	1	CARDINAL
dpc-1881	535	2	6-1881	DATE